Solvay, Wyeth to expand cooperation on anti-psychotic drugs |
|
|
|
Published
:
Thu, 11 Jan 2007 09:32
|
BRUSSELS (AFX) - Solvay SA said its pharmaceuticals unit and Wyeth Pharmaceuticals, a division of Wyeth, are expanding their joint development and sale of anti-psychotic drugs.Under their new agreement, the companies will work on the identification of small molecules with the potential to be used as anti-psychotic treatment.They will jointly own and patent any compounds discovered under this research collaboration.Their neuroscience development and commercialisation partnership, announced in April 2004, has resulted in a new drug application for bifeprunox for the treatment of schizophrenia.Development is continuing on two other early phase neuroscience projects SLV313 and SLV314, which were part of that agreement.victoria.main@afxnews.comvm/abr/harCOPYRIGHTCopyright AFX News Limited 2006. All rights reserved.The copying, republication or redistribution of AFX News Content, including by framing or similar means, is expressly prohibited without the prior written consent of AFX News.AFX News and AFX Financial News Logo are registered trademarks of AFX News Limited
|
|
|
|
Print this Story
WHO meet puts funds required to tackle bird flu at $1.5 billion 